Clinical Trials
Dry Age Related Macular Degeneration
Active Studies
GALE (Apellis)
A Phase 3, Open-label, Multicenter, Extension Study To Evaluate The Long-term Safety And Efficacy Of Pegcetacoplan In Subjects With Geographic Atrophy Secondary To Age-related Macular Degeneration.
HONU (Roche/Genentech)
A Multicenter, Prospective, Observational Study Of The Progression Of Intermediate Age-related Macular Degeneration.
iGAIN (Complement Therapeutics)
A Multicentre, Natural History, Non-interventional Study Evaluating Biomarkers In Participants With Geographic Atrophy(ga) Secondary To Age-related Macular Degeneration (AMD)
ONWARD (Alexion)
A Phase 2, Double Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
SIGLEC (Aviceda)
A Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Treatment Effect of Intravitreal AVD-104 in Participants with Geographic Atrophy Secondary to Age-related Macular Degeneration.
Completed Studies
AMEND (Smilebiotek)
A Phase 2, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing The Safety And Efficacy Of QA102 In Subjects With Dry Age-related Macular Degeneration (AMD).
ARCHER (Annexon)
A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
BEACON (Allergan)
A 2 Year, Phase 2 Study On The Safety And Efficacy Of Brimonidine Posterior Segment Drug Delivery System In Patients With Geography Atrophy Secondary To Age-related Macular Degeneration.
CATALINA (NGM Biopharmaceuticals)
A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
DERBY (Apellis)
A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
GALLEGO (Genentech)
A 18-month, Phase II, Multicenter, Randomized, Single-masked, Sham-controlled Study To Assess Safety, Tolerability, And Efficacy Of Intravitreal Injections Of FHTR2163 In Patients With Geographic Atrophy Secondary To Age-related Macular Degeneration.
GATHER 2 (Iveric)
A Phase 3 Multicenter, Randomized, Double-masked, Sham-controlled Clinical Trial To Assess The Safety And efficacy Of Intravitreal Administration Of Zimura™ (complement C5 Inhibitor) In Patients With Geographic atrophy Secondary To Dry Age-related Macular degeneration.
GR39821 (Genentech)
A Phase 1, Open-label, Single-dose, Dose-escalation, And Multiple-dose Study Of The Safety, Tolerability, Pharmacokinetics, And Immunogenicity Of Intravitreal Injections Of FHTR2163 In Patients With Geographic Atrophy Secondary To Macular Degeneration.
GR42163 (Genentech)
A Phase IA, Multicenter, Open-label, Single-dose, Dose-escalation Study Of The Safety, Tolerability, Pharmacokinetics, And Immunogenicity Of Intravitreal Injections Of RO7303359 In Patients With Geographic Atrophy Secondary To Age-related Macular Degeneration.
ICON (Pfizer)
A 1 Year Phase 2 Study Examining A Monoclonal Antibody To Decrease The Amount Of Drusen In The Eyes Seen In People With Dry AMD With An Intravenous Infusion.
OMASPECT (Genentech)
A Multicenter, Open-label Extension Study To Evaluate The Long-term Safety And Tolerability Of Lampalizumab In Patients With Geographic Atrophy Secondary To Age-related Macular Degeneration Who Have Completed A Roche-sponsored Study.
PREVENT IIT (NCRVA & Genentech)
A 2 Year Investigator Initiated Study On Prophylactic Ranibizumab For Exudative Age-related Macular Degeneration (AMD) In Vulnerable Eyes With Non Exudative AMD Trial.
SEATTLE (Acucela)
A 2 Year Phase 2/3 Study Which Aims To Reduce The Rate Of Dry AMD Progression With The Use Of An Pill.
SPECTRI (Genentech)
A 2 Year, Phase 3, Multicenter, Randomized, Double-masked, Sham-controlled Study To Assess The Efficacy And Safety Of Lampalizumab Administered Intravitreally To Patients With Geographic Atrophy Secondary To Age-related Macular Degeneration.
TARGETing GA (Santen Inc.)
Non-interventional, Cross-sectional Study Of Alu RNA Measurement And Complement Factor Genotyping Of Single Nucleotide Polymorphisms In The Complement Pathway In Patients With Geographic Atrophy Associated With Dry Age-related Macular Degeneration.
ZIMURA (Ophthotech)
A 18-month, Phase 2b Study On The Safety And Efficacy Of Zimura (Anti-c5 Aptamer) In Subjects With Geographic Atrophy Secondary To Dry Age-related Macular Degeneration.
